Healthcare Market Research Reports Analysis and Trends

Publication Single User License (PDF) Price
Global Hand Sanitizer Industry Report 2015

Global Hand Sanitizer Industry Report 2015

Date Published: Jun 30 2015
Global Hand Sanitizer Industry Report 2015 is a professional and in-depth study on the current state of the Hand Sanitizer industry.
 
The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Hand Sanitizer market analysis is provided for the China markets including development trends, competitive landscape analysis, and key regions development status.
 
$2,800.00
Global Nursing Pads Industry Report 2015

Global Nursing Pads Industry Report 2015

Date Published: Jun 29 2015
The Global Nursing Pads Industry Report 2015 is a professional and in-depth study on the current state of the Nursing Pads industry.
 
The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Nursing Pads market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.
 
$2,600.00
Belgium Pharmaceuticals and Healthcare Report Q3 2015

Belgium Pharmaceuticals and Healthcare Report Q3 2015

Date Published: Jun 24 2015
$1,295.00
Indonesia Pharmaceuticals and Healthcare Report Q3 2015

Indonesia Pharmaceuticals and Healthcare Report Q3 2015

Date Published: Jun 24 2015
Indonesia's healthcare expenditure will grow robustly. Key to this trajectory is rising household incomes which will have strong positive ramifications due to the dominant role of private spending as a source of healthcare financing. This will be further augmented by the roll out of universal healthcare which will improve access to medical services and in turn create commercial opportunities that will drive the expansion of private hospitals - a boon to Indonesia's healthcare infrastructure.
 
$1,295.00
Namibia Pharmaceuticals and Healthcare Report Q3 2015

Namibia Pharmaceuticals and Healthcare Report Q3 2015

Date Published: Jun 24 2015
$1,295.00
Qatar Pharmaceuticals and Healthcare Report Q3 2015

Qatar Pharmaceuticals and Healthcare Report Q3 2015

Date Published: Jun 24 2015
Qatar's Annual Health Report for 2014 confirms our view that the healthcare sector will experience strong growth over our forecast period. Sizeable expansion projects are underway, health insurance coverage is increasing and government spending will remain elevated given the substantial reserves. Growing private sector engagement will also drive healthcare market growth.
 

Headline Expenditure Projections 

$1,295.00
Serbia Pharmaceuticals and Healthcare Report Q3 2015

Serbia Pharmaceuticals and Healthcare Report Q3 2015

Date Published: Jun 24 2015
A focus on reining in Serbia's bloated public sector following an agreement with the IMF will inevitably lead to cuts in healthcare spending. Furthermore, Serbia's healthcare authorities will continue to cut prices to reduce their pharmaceutical expenditure as a means to contain healthcare costs. We expect the growth outlook for the Serbian pharmaceutical market to worsen in the short-term as household and government consumption decline.
 

Headline Expenditure Projections

$1,295.00
Spain Pharmaceuticals and Healthcare Report Q3 2015

Spain Pharmaceuticals and Healthcare Report Q3 2015

Date Published: Jun 24 2015
Spain's non-transparent and unpredictable government medicine pricing system and the implementation of numerous emergency measures to contain pharmaceutical spending will highly disrupt multinational drugmakers' strategy and revenue streams. Despite the Spanish economy exiting crisis mode, we believe that the Spanish government will continue to target the healthcare sector - a large recipient of government funds. As a result, we uphold our bearish outlook for the Spanish pharmaceutical market over the next five years.
 
$1,295.00
Sri Lanka Pharmaceuticals and Healthcare Report Q3 2015

Sri Lanka Pharmaceuticals and Healthcare Report Q3 2015

Date Published: Jun 24 2015
Domestic generic drugmakers will be at a distinct advantage under Sri Lanka's proposed national medicinal policy. With directives boosting generic drug sales through generic substitution, local pharmaceutical companies will be further assisted as the government aims to use the policy to reduce medicine imports. We highlight that these changes will come at the expense of drugmakers in India and Bangladesh, which have been a key source of pharmaceutical imports into Sri Lanka.
 
$1,295.00
Ireland Pharmaceuticals and Healthcare Report Q3 2015

Ireland Pharmaceuticals and Healthcare Report Q3 2015

Date Published: Jun 17 2015
$1,295.00
Israel Pharmaceuticals and Healthcare Report Q3 2015

Israel Pharmaceuticals and Healthcare Report Q3 2015

Date Published: Jun 17 2015
Drug price cuts and the addition of new pharmaceuticals to the national drug formulary demonstrate the government's commitment to expanding access to healthcare. Healthcare spending will remain elevated despite the fiscal deficit given the sector's importance in social stability.
 

Headline Expenditure Projections 

$1,295.00
Italy Pharmaceuticals and Healthcare Report Q3 2015

Italy Pharmaceuticals and Healthcare Report Q3 2015

Date Published: Jun 17 2015
Drugmakers will continue to face revenue earning challenges in Italy. In 2014, spending by Italy's national healthcare service, Servizio Sanitario Nazionale (SSN), fell for the seventh consecutive year in which SSN spending on drugs declined. SSN pharmaceutical expenditure will decline in 2015 - creating further revenue pressures for drugmakers as well as pharmacies in Italy and increasing out-of-pocket costs for the population.
 
$1,295.00
China Pharmaceuticals and Healthcare Report Q3 2015

China Pharmaceuticals and Healthcare Report Q3 2015

Date Published: Jun 17 2015
Multinational pharmaceutical companies will continue to invest and grow their presence in China, despite the slowdown in the economy. Driving this outlook is the outperformance of the pharmaceutical sector as authorities continue to improve healthcare access through stronger medical subsidies and an expansion of insurance coverage. In addition, reforms in the pharmaceutical sector, including the removal of price caps, will shift the industry towards a market-based system that further augments the commercial prospects.
 
$1,295.00
Moldova Pharmaceuticals and Healthcare Report Q3 2015

Moldova Pharmaceuticals and Healthcare Report Q3 2015

Date Published: Jun 17 2015
Moldova is heavily dependent on the success of outside sources, such as the European and Russian economy. In this regard, Moldova's economy is continuing to suffer greatly from the declining euro vs the US dollar and GBP combined with the full force of Western sanctions against the Russian Economy, as well as the drop in global oil prices. Indeed, a sluggish road is ahead for market growth in Moldova. However, increased purchasing power from outside investors could spark premature growth.
 
$1,295.00
Morocco Pharmaceuticals and Healthcare Report Q3 2015

Morocco Pharmaceuticals and Healthcare Report Q3 2015

Date Published: Jun 17 2015
Similar to other North African markets, Morocco's inclusion on PhRMA's Special 301 Submission for 2015 for intellectual property and pricing issues highlights the ongoing challenges that multinational drugmakers face in the market. However, we expect innovative drugmakers to continue seeking opportunities in Morocco, particularly with recent updates to the intellectual property law that highlights the country's commitment to improving the operating environment for multinationals.
 
$1,295.00
Philippines Pharmaceuticals and Healthcare Report Q3 2015

Philippines Pharmaceuticals and Healthcare Report Q3 2015

Date Published: Jun 17 2015
Innovative pharmaceutical companies will continue to face a challenging business environment in the Philippines. Many concerns limiting the sales of patented drugs in the country remain unaddressed, including the low levels of intellectual property protection. Furthermore, pricing pressures on innovative drugs continue to intensify as the government seeks to expand universal healthcare coverage while reducing government debt.
 
$1,295.00
Saudi Arabia Pharmaceuticals and Healthcare Report Q3 2015

Saudi Arabia Pharmaceuticals and Healthcare Report Q3 2015

Date Published: Jun 17 2015
Over the forthcoming years, growth in Saudi Arabia's pharmaceutical market will remain elevated. The government's commitment to the sector and health insurance expansion will be key drivers of sector growth, with the risks from lower oil prices and the Gulf Cooperation Council drug price unification process remaining minimal.
 

Headline Expenditure Projections 

$1,295.00
Bangladesh Pharmaceuticals and Healthcare Report Q3 2015

Bangladesh Pharmaceuticals and Healthcare Report Q3 2015

Date Published: Jun 17 2015
$1,295.00
Slovakia Pharmaceuticals and Healthcare Report Q3 2015

Slovakia Pharmaceuticals and Healthcare Report Q3 2015

Date Published: Jun 17 2015
Eurozone recovery and an improving domestic economic outlook will provide a boost to healthcare expenditure in Slovakia in the short-term. Over the longer term, we expect healthcare spending to accelerate given Slovakia's ageing population and burden of chronic diseases. With public finances on firmer footing and a centre-left government promising more generous social spending, multinational drugmakers and medical device companies can expect to see growth in revenues from Slovakia.
 
$1,295.00
Cuba Pharmaceuticals and Healthcare Report Q3 2015

Cuba Pharmaceuticals and Healthcare Report Q3 2015

Date Published: Jun 17 2015
$1,295.00

Pages

Shopping cart

0 Items $0.00
Not able to find what you are looking for?
Call Us
WHY CHOOSE MARKET RESEARCH REPORTS?
1
Trusted By Leaders
2
Shop With Confidence
3
Customer Centric
4
Personalized Solutions
5
Secure Checkout

User login

Clients Who Trust Us

Orange, Google, Microsoft, Barclays, CassidianIntel, TPG, Elit Net, Cross Business Producers, AcmavolpakP&G, Cisco, Gemalto, General Insurance Corporation of India, Aviva, Cognizant, InoxWindB. Braun, Cobham, fiserv, Harris, Wipro, AonAl Meera, Nomura Research Institute, Tata Consultancy Services, Amara Raja, Hiranandani EnergyMunich Re, Lotte Chemical, National Post, First Data